Proactive Investors - Run By Investors For Investors

Zogenix stock plunges after FDA refuses to review seizure drug

In a refusal-to-file letter, the FDA pointed to an incorrect version of a dataset in the company’s application
brain and brain waves
Fintepla is a treatment for seizures associated with Dravet syndrome.

Zogenix Inc (NASDAQ:ZGNX) is reeling after the Food and Drug Administration late Thursday refused to review the company’s new drug application for Fintepla, a treatment for seizures associated with Dravet syndrome.

In a refusal-to-file letter, the FDA pointed to an incorrect version of a dataset in the Emeryville, California company’s application and the exclusion of certain non-clinical studies, which prevented the administration from completing a review.

The drugmaker is seeking a Type A – high priority – meeting with the FDA to address the concerns.

READ: Zogenix shares pop on impressive Phase 3 results for epilepsy drug

“We remain highly confident in Fintepla’s clinical profile demonstrated in the Phase 3 program in Dravet syndrome and are committed to advancing the product candidate as a potential new treatment option,” President and CEO Stephen J. Farr said. “We are fully committed to working with the FDA as quickly as possible to address the open issues and clarify the path to successfully re-filing our application.”

Shares plummeted more than 22% to $40.22.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

View full ZGNX profile View Profile

Zogenix Timeline

Related Articles

cancerous cells
March 08 2019
A series of trials underway at major cancer research hospitals are evaluating the company's flagship cancer drug Ampligen
Oncoprex
October 17 2018
The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual
A double helix and a medical person
March 06 2019
Leronlimab, according to the company, is an antiviral agent candidate with fewer side effects, lower toxicity and less frequent doses than daily HIV therapies now in use
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use